Preparation and properties of polyaniline‐silver composite by glucose reduction

2021 ◽  
Author(s):  
Zhuowei Han ◽  
Qi Liu ◽  
Hui Zhao ◽  
Yujing Shi ◽  
Yinuo Liu ◽  
...  
Keyword(s):  
Glucose Reduction ◽  
Silver Composite

Application of Innovative Hydroxyapatite Materials in 3D Printing for Biocompatible Voice Implants

2018 ◽  
Vol 69 (4) ◽  
pp. 840-842
Author(s):  
Wojciech Musialik ◽  
Marcin Nabialek ◽  
Slawomir Letkiewicz ◽  
Andrei Victor Sandu ◽  
Katarzyna Bloch
Keyword(s):  
3D Printing ◽  
Surgical Procedures ◽  
Bacterial Infections ◽  
Fungal Infections ◽  
Colloidal Silver ◽  
Bone Implants ◽  
External Ring ◽  
Voice Prostheses ◽  
3D Printers ◽  
Silver Composite

The paper presents the possibility of using an innovative hydroxyapatite filament Ca10(PO4)6(OH)2 for printing in 3D printers of bone implants and the possibility of using it during implantation with voice prostheses. The introduction of an additional colloidal silver composite in voice implants will contribute to the reduction of bacterial infections, fungal infections and granulomatous hyperplasia. The creation of a stable external ring of the vocal fistula will remove complications associated with it with enlargement of the fistula and leakiness of voice implants. The ability to print with a hydroxyapatite filament will allow digital pre-surgery modeling of bone implants suited to the needs of surgical procedures.

Antibacterial activities of centrifugally spun polyethylene oxide/silver composite nanofibers

2021 ◽  
Author(s):  
Md Toukir Hasan ◽  
Ramiro Gonzalez ◽  
Mircea Chipara ◽  
Luis Materon ◽  
Jason Parsons ◽  
...  
Keyword(s):  
Polyethylene Oxide ◽  
Composite Nanofibers ◽  
Antibacterial Activities ◽  
Silver Composite

Comparative free radical scavenging and hypoglycemic activities of n-hexane, ethyl-acetate, and aqueous fractions of Azanza garckeana pulp

2021 ◽  
Vol 1 (2) ◽  
pp. 1-8
Author(s):  
Abubakar A. Yusuf ◽  
Toheeb D. Yissa ◽  
Abdulhakeem Rotimi Agboola ◽  
Sodiq M Balogun ◽  
Peter O. Adeboye ◽  
...  
Keyword(s):  
Ethyl Acetate ◽  
Radical Scavenging ◽  
Ethyl Acetate Fraction ◽  
Diabetic Rats ◽  
Hypoglycemic Effect ◽  
Hexane Fraction ◽  
Dependent Manner ◽  
Aqueous Fraction ◽  
Dpph Scavenging ◽  
Glucose Reduction

Background: The prevalence of diabetes mellitus is increasing on a global trend. The aim of the present study is to identify the most effective antioxidants and hypoglycemic fraction of Azanza garckeana. Methods: The fractions (nhexane or ethyl-acetate or aqueous) of A. garckeana were administered to the alloxan-induced diabetic rats at doses of 100, 200, and 400 mg/kg for 15 days. Antioxidants activities were evaluated at concentrations of 62.5, 125, 250, and 500 µg/mL using the DPPH scavenging assay. Results: Results revealed that both the hexane, ethyl-acetate, and aqueous fractions exhibited hypoglycemic and antioxidants activities in a dose-dependent manner. The n-hexane fraction demonstrated highest percentage DPPH scavenging effect of 26.34±3.43, 38.44±4.35, 59.34±3.45, and 74.83±5.35 at 62.5, 125, 250, and 500 µg/mL respectively. The ethyl-acetate fraction demonstrated 19.33±2.98, 28.94±3.24, 47.34±2.90, and 57.82±4.54 respectively while the aqueous fraction exhibited the least activities of 12.45±23.45, 18.64±2.94, 27.94±3.89, and 39.43±3.89 at concentrations of 62.5, 125, 250, and 500 µg/mL respectively. In addition, the n-hexane fraction demonstrated the most significant hypoglycemic effect with the highest glucose reduction of 58.97 ±3.45 %, 63.86±5.35 %, and 66.51±4.35 %, ethyl acetate fraction demonstrated glucose reduction of 7.55±0.54%, 21.77±2.35 %, and 29.56±3.46 % while the aqueous fraction demonstrated the least hypoglycemic effect of 9.89±2.67 %, 18.09±3.45 %, and 18.87±3.24 at 100, 200 and 400 mg/kg bw respectively. Conclusion: The n-hexane fraction of Azanza garckeana extract could serve as a reservoir of bioactive agents that could be useful for the development of a new anti-diabetic agent

scholarly journals The Liver Circadian Clock Modulates Biochemical and Physiological Responses to Metformin

2017 ◽  
Vol 32 (4) ◽  
pp. 345-358 ◽  
Author(s):  
Emma Henriksson ◽  
Anne-Laure Huber ◽  
Erin K. Soto ◽  
Anna Kriebs ◽  
Megan E. Vaughan ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Time Of Day ◽  
Glucose Response ◽  
Biological Responses ◽  
Circadian Time ◽  
Lower Blood ◽  
Life Threatening ◽  
Lactate Levels ◽  
Amp Activated Protein Kinase ◽  
Glucose Reduction

Metformin is widely used in the treatment of type 2 diabetes to lower blood glucose. Although metformin is a relatively safe and effective drug, its clinical efficacy is variable and under certain circumstances it may contribute to life-threatening lactic acidosis. Thus, additional understanding of metformin pharmacokinetics and pharmacodynamics could provide important information regarding therapeutic use of this widely prescribed drug. Here we report a significant effect of time of day on acute blood glucose reduction in response to metformin administration and on blood lactate levels in healthy mice. Furthermore, we demonstrate that while metformin transport into hepatocytes is unaltered by time of day, the kinetics of metformin-induced activation of AMP-activated protein kinase (AMPK) in the liver are remarkably altered with circadian time. Liver-specific ablation of Bmal1 expression alters metformin induction of AMPK and blood glucose response but does not completely abolish time of day differences. Together, these data demonstrate that circadian rhythms affect the biological responses to metformin in a complex manner.

Prolonged blood glucose reduction in mrp-2 deficient rats (GY/TR−) by the glucose-6-phosphate translocase inhibitor S 3025

2002 ◽  
Vol 1569 (1-3) ◽  
pp. 105-110 ◽  
Author(s):  
Andreas W. Herling ◽  
Dietmar Schwab ◽  
Hans-Joerg Burger ◽  
Jochen Maas ◽  
Roland Hammerl ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glucose Reduction

scholarly journals Rapid Weight Loss, Central Obesity Improvement and Blood Glucose Reduction Are Associated with a Stronger Adaptive Immune Response Following COVID-19 mRNA Vaccine

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 79
Author(s):  
Mikiko Watanabe ◽  
Angela Balena ◽  
Davide Masi ◽  
Rossella Tozzi ◽  
Renata Risi ◽  
...  
Keyword(s):  
Immune Response ◽  
Weight Loss ◽  
Blood Glucose ◽  
Adaptive Immune Response ◽  
Humoral Response ◽  
Rapid Weight Loss ◽  
Low Carbohydrate Diet ◽  
Adaptive Immune ◽  
Glucose Reduction ◽  
The Impact

Obesity is associated with a poor COVID-19 prognosis, and it seems associated with reduced humoral response to vaccination. Public health campaigns have advocated for weight loss in subjects with obesity, hoping to eliminate this risk. However, no evidence proves that weight loss leads to a better prognosis or a stronger immune response to vaccination. We aimed to investigate the impact of rapid weight loss on the adaptive immune response in subjects with morbid obesity. Twenty-one patients followed a hypocaloric, very-low-carbohydrate diet one week before to one week after the two mRNA vaccine doses. The diet’s safety and efficacy were assessed, and the adaptive humoral (anti-SARS CoV-2 S antibodies, Abs) and cell-mediated responses (IFNγ secretion on stimulation with two different SARS CoV-2 peptide mixes, IFNγ-1 and IFNγ-2) were evaluated. The patients lost ~10% of their body weight with metabolic improvement. A high baseline BMI correlated with a poor immune response (R −0.558, p = 0.013 for IFNγ-1; R −0.581, p = 0.009 for IFNγ-2; R −0.512, p = 0.018 for Abs). Furthermore, there was a correlation between weight loss and higher IFNγ-2 (R 0.471, p = 0.042), and between blood glucose reduction and higher IFNγ-1 (R 0.534, p = 0.019), maintained after weight loss and waist circumference reduction adjustment. Urate reduction correlated with higher Abs (R 0.552, p = 0.033). In conclusion, obesity is associated with a reduced adaptive response to a COVID-19 mRNA vaccine, and weight loss and metabolic improvement may reverse the effect.

scholarly journals Investigation of possible underlying mechanisms behind water-induced glucose reduction in adults with high copeptin

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sofia Enhörning ◽  
Tiphaine Vanhaecke ◽  
Alberto Dolci ◽  
Erica T. Perrier ◽  
Olle Melander
Keyword(s):  
Urine Volume ◽  
Surrogate Marker ◽  
Oral Glucose ◽  
Glucose Lowering ◽  
Glucose Lowering Effect ◽  
Urine Cortisol ◽  
Underlying Mechanisms ◽  
Glucose Reduction ◽  
Water Supplementation ◽  
Pituitary Adrenal Axis

AbstractElevated copeptin, a surrogate marker of vasopressin, is linked to low water intake and increased diabetes risk. Water supplementation in habitual low-drinkers with high copeptin significantly lowers both fasting plasma (fp) copeptin and glucose. This study aims at investigating possible underlying mechanisms. Thirty-one healthy adults with high copeptin (> 10.7 pmol·L−1 (men), > 6.1 pmol−1 (women)) and 24-h urine volume of < 1.5L and osmolality of > 600 mOsm·kg−1 were included. The intervention consisted of addition of 1.5 L water daily for 6 weeks. Fp-adrenocorticotropic hormone (ACTH), fp-cortisol, 24-h urine cortisol, fasting and 2 h (post oral glucose) insulin and glucagon were not significantly affected by the water intervention. However, decreased (Δ baseline-6 weeks) fp-copeptin was significantly associated with Δfp-ACTH (r = 0.76, p < 0.001) and Δfp-glucagon (r = 0.39, p = 0.03), respectively. When dividing our participants according to baseline copeptin, median fp-ACTH was reduced from 13.0 (interquartile range 9.2–34.5) to 7.7 (5.3–9.9) pmol L−1, p = 0.007 in the top tertile of copeptin, while no reduction was observed in the other tertiles. The glucose lowering effect from water may partly be attributable to decreased activity in the hypothalamic–pituitary–adrenal axis.ClinicalTrials.gov: NCT03574688.

Sign in / Sign up

Export Citation Format

Share Document